Clinical pharmacokinetics of Azilsartan medoxomil for the treatment of cardiovascular disease: A review

14th International Conference on Science, Engineering and Technology

自然科学;工业技术

Sangeetha, D.^1 ; Senthil Kumar, M.^1,2

Department of Chemistry, School of Advanced Sciences, VIT University, Vellore, Tamil Nadu

632 014, India^1

Syngeneic International Limited, Bangalore

560099, India^2

关键词: Candidate selection;    Cardio-vascular disease;    Clinical effects;    Clinical pharmacokinetics;    Clinical trial;    Co morbidities;    Drug discovery;    New chemical entities;   

Others  :  https://iopscience.iop.org/article/10.1088/1757-899X/263/2/022032/pdf
DOI  :  10.1088/1757-899X/263/2/022032

来源: IOP

【 摘 要 】

Hypertension related cardiovascular complications could be amplified by the presence of metabolic co-morbidities. Azilsartan medoxomil is a precise blocker of angiotensin 1 receptor that prevent angiotenin binding, resulting in vasodilation and decrease the effects of aldosterone. Azilsartan is a recently approved angiotensin 1 receptor blocker and appears to be more efficacious in reducing blood pressure than other blockers with a similar safety and tolerability profile. Its very high affinity to and slow dissociation from the angiotensin 1 receptor along with its inverse agonistic properties make it a very good candidate for clinical effects beyond simple blood pressure control, potentially counteracting cardiac hypertrohy and cardiac fibrosis. In drug discovery and the development is to optimize candidate selection for the target therapeutic area and to predict the dose and dosing regime for initial clinical trials with due consern to the requirements for effective treatment in the target therapeutic area these are the main role of preclinical pharmacokinetics. Both the pharmaceutical target and drug disposition like absorption, clearance and distribution of new chemical entities with clear understanding and consideration is required for the type of agent and in sequence for the successful approach.